Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it

Current Opinion in Structural Biology

Volumn 19, Issue 4, 2009, Pages 408-417

  Lee, Jeffrey E ^a   Saphire, Erica Ollmann ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTEGRIN; CD209 ANTIGEN; EBOLA VACCINE; EPITOPE; FOLATE RECEPTOR; HIGH MOBILITY GROUP PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

CRYSTAL STRUCTURE; DRUG DESIGN; DRUG TARGETING; EBOLA VIRUS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EBOLAVIRUS; HUMANS; MUCINS; PROTEIN STRUCTURE, TERTIARY; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EBOLA VIRUS;

EID: 69249132055     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2009.05.004     Document Type: Review

References (56)

1. Jahrling P.B., Geisbert T.W., Dalgard D.W., Johnson E.D., Ksiazek T.G., Hall W.C., and Peters C.J. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335 (1990) 502-505
2. Le Guenno B., Formentry P., Wyers M., Gounon P., Walker F., and Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345 (1995) 1271-1274
3. Sanchez A., Yang Z.Y., Xu L., Nabel G.J., Crews T., and Peters C.J. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 72 (1998) 6442-6447
4. Sanchez A., Trappier S.G., Mahy B.W., Peters C.J., and Nichol S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA 93 (1996) 3602-3607
5. Feldmann H., Volchkov V.E., Volchkova V.A., and Klenk H.D. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl 15 (1999) 159-169
6. Feldmann H., Volchkov V.E., Volchova V.A., Stroher U., and Klenk H.D. Biosynthesis and role of filoviral glycoproteins. J Gen Virol 82 (2001) 2839-2848
7. Sanchez A., Khan A.S., Zaki S.R., Nabel G.J., Ksiazek T.G., and Peters C.J. Filoviridae: Marburg and Ebola viruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott, Williams, and Wilkins 1279-1304
8. Baize S., Leroy E.M., Georges-Courbot M.C., Capron M., Lansoud-Soukate J., Debre P., Fisher-Hoch S.P., McCormick J.B., and Georges A.J. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5 (1999) 423-426
9. Sanchez A., Lukwiya M., Bausch D., Mahanty S., Sanchez A.J., Wagoner K.D., and Rollin P.E. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78 (2004) 10370-10377
10. Ksiazek T.G., Rollin P.E., Williams A.J., Bressler D.S., Martin M.L., Swanepoel R., Burt F.J., Leman P.A., Khan A.S., Rowe A.K., et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179 Suppl 1 (1999) S177-S187
11. Leroy E.M., Baize S., Volchkov V.E., Fisher-Hoch S.P., Georges-Courbot M.C., Lansoud-Soukate J., Capron M., Debre P., McCormick J.B., and Georges A.J. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355 (2000) 2210-2215
12. Gupta M., Mahanty S., Greer P., Towner J.S., Shieh W.J., Zaki S.R., Ahmed R., and Rollin P.E. Persistent infection with ebola virus under conditions of partial immunity. J Virol 78 (2004) 958-967
13. Dolnik O., Volchkova V., Garten W., Carbonnelle C., Becker S., Kahnt J., Stroher U., Klenk H.D., and Volchkov V. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23 (2004) 2175-2184
14. Volchkov V.E., Volchkova V.A., Slenczka W., Klenk H.D., and Feldmann H. Release of viral glycoproteins during Ebola virus infection. Virology 245 (1998) 110-119
15. Maruyama T., Parren P.W., Sanchez A., Rensink I., Rodriguez L.L., Khan A.S., Peters C.J., and Burton D.R. Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 179 Suppl. 1 (1999) S235-S239. This paper describes the first set of human antibodies against ebolavirus infection, identified in outbreak survivors.
16. Kudoyarova-Zubavichene N.M., Sergeyev N.N., Chepurnov A.A., and Netesov S.V. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 179 Suppl. 1 (1999) S218-S223
17. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., Custers J.H., Popernack P.M., Yang Z.Y., Pau M.G., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3 (2006) e177
18. Takada A., Ebihara H., Jones S., Feldmann H., and Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25 (2007) 993-999
19. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., Aman M.J., and Bavari S. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 100 (2003) 15889-15894
20. Mupapa K., Massamba M., Kibadi K., Kumula K., Bwaka A., Kipasa M., Coleblunders R., and Muyembe-Tamfum J.J. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179 (1999) S18-S23
21. Sadek R.F., Khan A.S., Stevens G., Peters C.J., and Ksiazek T.G. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 179 Suppl. 1 (1999) S24-S27
22. Lee J.E., Fusco M.H., Hessell A.J., Oswald W.B., Burton D.R., and Saphire E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454 (2008) 177-183. This paper describes the first structure of the prefusion, trimeric ebolavirus glycoprotein in complex with a neutralizing antibody identified from a human survivor of the 1995 Kikwit, Zaire outbreak and provides a model for ebolavirus entry and future therapeutic development.
23. Weissenhorn W., Carfi A., Lee K.H., Skehel J.J., and Wiley D.C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 2 (1998) 605-616
24. Malashkevich V.N., Schneider B.J., McNally M.L., Milhollen M.A., Pang J.X., and Kim P.S. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å resolution. Proc Natl Acad Sci USA 96 (1999) 2662-2667
25. Lee J.E., Fusco M.H., and Saphire E.O. An efficient platform for screening expression and crystallization of glycoproteins produced in human cells. Nat Protocols 4 (2009) 592-604
26. Wilson I.A., Skehel J.J., and Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289 (1981) 366-373
27. Yin H.S., Wen X., Paterson R.G., Lamb R.A., and Jardetzky T.S. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439 (2006) 38-44
28. Rey F.A., Heinz F.X., Mandl C., Kunz C., and Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375 (1995) 291-298
29. Roche S., Rey F.A., Gaudin Y., and Bressanelli S. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315 (2007) 843-848
30. Heldwein E.E., Lou H., Bender F.C., Cohen G.H., Eisenberg R.J., and Harrison S.C. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313 (2006) 217-220
31. Harrison S.C. Viral membrane fusion. Nat Struct Mol Biol 15 (2008) 690-698
32. Lamb R.A., and Jardetzky T.S. Structural basis of viral invasion: lessons from paramyxovirus F. Curr Opin Struct Biol 17 (2007) 427-436
33. White J.M., Delos S.E., Brecher M., and Schornberg K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43 (2008) 189-219. A thorough and informative review on the three classes of viral membrane fusion proteins and their mechanisms of viral entry.
34. Alvarez C.P., Lasala F., Carrillo J., Muniz O., Corbi A.L., and Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76 (2002) 6841-6844
35. Chan S.Y., Empig C.J., Welte F.J., Speck R.F., Schmaljohn A., Kreisberg J.F., and Goldsmith M.A. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106 (2001) 117-126
36. Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T., Jones S., Feldmann H., and Kawaoka Y. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 80 (2006) 10109-10116
37. Takada A., Fujioka K., Tsuiji M., Morikawa A., Higashi N., Ebihara H., Kobasa D., Feldmann H., Irimura T., and Kawaoka Y. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 78 (2004) 2943-2947
38. Takada A., Watanabe S., Ito H., Okazaki K., Kida H., and Kawaoka Y. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278 (2000) 20-26
39. Brindley M.A., Hughes L., Ruiz A., McCray Jr. P.B., Sanchez A., Sanders D.A., and Maury W. Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol 81 (2007) 7702-7709
40. Manicassamy B., Wang J., Jiang H., and Rong L. Comprehensive analysis of Ebola virus GP1 in viral entry. J Virol 79 (2005) 4793-4805
41. Mpanju O.M., Towner J.S., Dover J.E., Nichol S.T., and Wilson C.A. Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry. Virus Res 121 (2006) 205-214
42. Kuhn J.H., Radoshitzky S.R., Guth A.C., Warfield K.L., Li W., Vincent M.J., Towner J.S., Nichol S.T., Bavari S., Choe H., et al. Conserved receptor-binding domains of Lake Victoria Marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 281 (2006) 15951-15958
43. Dube D., Brecher M.B., Delos S.E., Rose S.C., Park E.W., Schornberg K.L., Kuhn J.H., and White J.M. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol 83 (2009) 2883-2891
44. Chandran K., Sullivan N.J., Felbor U., Whelan S.P., and Cunningham J.M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308 (2005) 1643-1645. This paper describes the original identification of the essential role for cathepsin B and L in ebolavirus GP-mediated entry.
45. Kaletsky R.L., Simmons G., and Bates P. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol 81 (2007) 13378-13384
46. Schornberg K., Matsuyama S., Kabsch K., Delos S., Bouton A., and White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 80 (2006) 4174-4178
47. Freitas M.S., Gaspar L.P., Lorenzoni M., Almeida F.C., Tinoco L.W., Almeida M.S., Maia L.F., Degreve L., Valente A.P., and Silva J.L. Structure of the Ebola fusion peptide in a membrane-mimetic environment and the interaction with lipid rafts. J Biol Chem 282 (2007) 27306-27314
48. Maruyama T., Rodriguez L.L., Jahrling P.B., Sanchez A., Khan A.S., Nichol S.T., Peters C.J., Parren P.W., and Burton D.R. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73 (1999) 6024-6030
49. ••]) characterizes a series of murine antibodies and identifies its protective epitope on the ebolavirus glycoprotein.
50. Wilson J.A., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A.L., and Hart M.K. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287 (2000) 1664-1666. This study identifies a series of protective murine antibodies, directed towards five unique epitopes on the ebolavirus GP that protect mice against lethal EBOV challenge up to two days post-exposure.
51. Parren P.W.H.I., Geisbert T.W., Maruyama T., Jahrling P.B., and Burton D.R. Pre- and post-exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76 (2002) 6408-6412
52. Oswald W.B., Geisbert T.W., Davis K.J., Geisbert J.B., Sullivan N.J., Jahrling P.B., Parren P.W., and Burton D.R. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3 (2007) 62-66
53. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., Goudsmit J., and Wilson I.A. Antibody recognition of a highly conserved influenza virus epitope. Science 324 (2009) 246-251
54. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Caldwell G., Ali M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16 (2009) 265-273
55. Shahhosseini S., Das D., Qiu X., Feldmann H., Jones S.M., and Suresh M.R. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J Virol Methods 143 (2007) 29-37
56. Lee J.E., Kuehne A., Abelson D.M., Fusco M.L., Hart M.K., and Saphire E.O. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda × light chain. J Mol Biol 375 (2008) 202-216